Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.54 |
| ▸ | ATR | Q13535 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963739 | 0.92 | F10 (0.62) | MAP4K4F10ATRALDH1A1GPR52 | |
| SCHEMBL957882 | 0.86 | MAP4K4 (0.54) | MAP4K4F10ATRALDH1A1ERN1 | |
| SCHEMBL961526 | 0.81 | MAP4K4 (0.56) | MAP4K4ATRALDH1A1GPR52ERN1 | |
| SCHEMBL958254 | 0.80 | MAP4K4 (0.54) | MAP4K4ATRERN1MEN1KMT2A | |
| SCHEMBL958719 | 0.80 | MAP4K4 (0.54) | MAP4K4ATRALDH1A1ERN1MEN1 | |
| SCHEMBL958209 | 0.79 | NR4A2 (0.63) | — | |
| SCHEMBL962920 | 0.77 | CNR2 (0.57) | ALDH1A1MEN1KMT2A | |
| SCHEMBL961496 | 0.75 | SMYD2 (0.56) | MAP4K4GPR52DRD4 | |
| SCHEMBL960760 | 0.74 | GPR52 (0.53) | MAP4K4F10ATRGPR52MEN1 | |
| SCHEMBL12918939 | 0.73 | MAP4K4 (0.51) | MAP4K4ATRERN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | MAP4K4 2519/4885F10 2704/4885ATR 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.